Credit Suisse analyst Kaumil Gajrawala maintains Coca-Cola (NYSE:KO) with a Outperform and lowers the price target from $68 to $64.
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
In the last three months, 12 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:APLS), offering a diverse range…